The once-daily tablet covers weight management and type 2 diabetes. Trial patients lost about 5% to 11% of body weight over 72 weeks, per EMA.
Recap by typeshit. Full story at European Medicines Agency (EMA).
Fiscal.ai posted a chart comparing Lilly and Novo Nordisk and says Lilly is pulling ahead in the obesity drug market. Only the chart is shared, with no other detail.
A short clip of Rosie O'Donnell discussing the tirzepatide drug Mounjaro. Few details are given beyond the title.
Sam Stone mixed GLP-1 Daily Support powder into a smoothie daily and came away with stomach aches and doubts about what it does.
Dr Desmond Wai shares the Novo Nordisk news and notes the FDA cleared semaglutide for fatty liver disease in the US more than a year earlier.
The group's letter to the acting FDA commissioner says all favorable votes on BPC-157, TB-500 and others came from newly appointed members.
A French clip flags dry mouth and reflux in GLP-1 patients, plus a specific risk to watch for before sedation.
Loading…